Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03383419 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients

Study acronym: TROJAN-C
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Active, Not Recruiting to Recruiting
    • Primary and study completion dates: Dec 30, 2025 to Dec 30, 2026
    • Site details revised at 3 of 3 sites
    v10
  2. Primary and study completion dates: Dec 30, 2023 to Dec 30, 2025v9
  3. Primary and study completion dates: Dec 30, 2022 to Dec 30, 2023
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 20 to confirmed 15
    • Site details revised at 3 of 3 sites
    v8
  4. Primary completion date: Jan 30, 2021 to Dec 30, 2022
    • Study completion date: Feb 28, 2021 to Dec 30, 2022
    • Site contacts updated at 1 of 3 sites
    v7
  5. Primary completion date: Mar 30, 2020 to Jan 30, 2021
    • Study completion date: Dec 31, 2020 to Feb 28, 2021
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Eligibility criteria shortened, about 28 words
    • Site details revised at 2 of 3 sites
    v5
  2. Site details revised at 2 of 3 sitesv4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 3
    • Start date changed from estimate of Mar 1, 2018 to Mar 20, 2018
    v3
  4. Phase: Phase 4 to Phase 2v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).
Trial Details
NCT Number NCT03383419
Lead Sponsor Baylor Research Institute
Conditions
(from sponsor)		 Heart Failure
Related terms Heart Failure
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov